Volta logo.jpg
Volta Medical Announces Completion of Patient Enrollment in TAILORED-AF Clinical Trial for Treatment of Atrial Fibrillation
February 02, 2023 08:00 ET | Volta Medical
• First randomized controlled clinical trial to evaluate VX1-guided ablation compared to conventional anatomical ablation approaches to treat persistent atrial fibrillation• International,...
Volta logo.jpg
Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced
January 05, 2023 08:00 ET | Volta Medical
New round of financing led by Vensana Capital will support technology platform expansion and further validating VX1, Volta’s Artificial Intelligence (AI) Decision-Support Software in improving...
Logo Volta Medical.png
Volta Medical’s AI based solution for patients in atrial fibrillation achieves robust validation in first peer-reviewed publication
August 31, 2022 08:00 ET | Volta Medical
Volta VX1 decision support software reproduces expert-physician electrogram (EGM) analysis that can assist physicians in the real-time identification of specific abnormal electrograms in a persistent...
Volta logo.jpg
Volta Medical VX1 AI Software to be Featured at Heart Rhythm 2022
April 27, 2022 08:00 ET | Volta Medical
-  Company’s VX1 AI software for use in atrial fibrillation will be featured during several events at the Congress - MARSEILLE, France and PROVIDENCE, R.I., April 27, 2022 (GLOBE NEWSWIRE) -- Volta...
Volta logo.jpg
First U.S. patients with persistent cardiac arrythmias treated using Volta Medical’s artificial intelligence-based analysis
December 21, 2021 08:00 ET | Volta Medical
Novel, FDA-cleared and CE-certified medical device is designed to help cardiologists identify cardiac abnormalities in patients undergoing ablation treatment for persistent, drug-resistant atrial...